EGRX Eagle Pharmaceuticals Inc.

Final Reminder: Eagle Pharmaceuticals to Host 2016 Investor Day in New York City

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--

Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (NASDAQ:EGRX) today issued a final reminder regarding its previously announced 2016 Investor Day. The event will be held on Friday, November 11, 2016 at the Pierre Hotel located at 2 East 61st Street, New York City. The meeting, which also will be webcast live, will begin promptly at 8:00 a.m. Eastern Standard Time (EST) and end at approximately 11:30 a.m. EST. Breakfast and registration will begin at 7:00 a.m.

Institutional investors and analysts who have not already registered and are interested in attending the event can RSVP to Lisa Wilson, Investor Relations for Eagle Pharmaceuticals, either via telephone at 1-212-452-2793 or e-mail at [email protected].

Institutional investors and analysts unable to attend in person are invited to listen to the investor meeting via a live audio webcast which can be viewed on the Investor Relations section of the Company's website at www.eagleus.com.

A webcast replay will be available for on-demand listening shortly after the completion of the event for 90 days, at the aforementioned section, also at www.eagleus.com.

About Eagle Pharmaceuticals, Inc.

Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle’s strategy is to utilize the FDA's 505(b)(2) regulatory pathway. Additional information is available on the company’s website at www.eagleus.com.

EN
01/11/2016

Underlying

EGRXEagle Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Eagle Pharmaceuticals Inc.

 PRESS RELEASE
Free
EGRX Eagle Pharmaceu...

Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BEND...

Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties WOODCLIFF LAKE, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that it has entered into a royalty purchase agreement with an entity that was provided capital by funds managed by Blue Owl Capital Inc. (“Blue Owl”) (the “Agreement”), dated March 31, 2025, to sell the royalty interest in annual net sales of BENDEKA® (bendamustine hydrochloride injection) in the United States for an aggregate purchase price of $69 million before ...

March 31, 2025 1 EN
 PRESS RELEASE
Free
EGRX Eagle Pharmaceu...

Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockhol...

Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan WOODCLIFF LAKE, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its Board of Directors (the “Board”) has approved an amendment to its previously disclosed limited duration stockholder rights plan (the “Rights Plan”) to increase the initial purchase price of each preferred share purchase right issued under the Rights Plan from $10.00 to $20.00, effective immediately. The Rights Plan otherwise remains unmodified and in ful...

March 21, 2025 1 EN
 PRESS RELEASE
Free
EGRX Eagle Pharmaceu...

Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financi...

Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer WOODCLIFF LAKE, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced the appointment of Christopher Krawtschuk as Chief Financial Officer (“CFO”) of the Company, effective November 11, 2024. In connection with Mr. Krawtschuk’s appointment, Mr. Steven Ratoff stepped down from his role as interim Chief Financial Officer and will remain as a director on the Company’s board of directors. “Chris is a talented finance executive with deep exp...

November 12, 2024 1 EN
 PRESS RELEASE
Free
EGRX Eagle Pharmaceu...

Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan

Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan WOODCLIFF LAKE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (the “Company” or “Eagle”) (OTCMKTS: EGRX) today announced that its Board of Directors (the “Board”) has adopted a limited duration stockholder rights agreement (the “Rights Plan”), effective immediately. The Company continues to experience a significant dislocation in the trading price of its common stock. The Rights Plan is intended to enable each of the Company’s stockholders to have the opportunity to realize the long-term value of ...

October 31, 2024 1 EN
 PRESS RELEASE
Free
EGRX Eagle Pharmaceu...

Eagle Pharmaceuticals Announces Receipt of Delisting Notification from...

Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq WOODCLIFF LAKE, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company” or “Eagle”) today announced that it received a notice (the “Notice”) on August 21, 2024, from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that pursuant to Nasdaq Listing Rule 5810(d)(2), the Company’s failure to timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the “Q2 2024 Form 10-Q”) serves as an...

August 27, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch